Circadian Rhythms of Aqueous Humor Dynamics in Humans

Inclusion Criteria

• Subjects must be nineteen (19) years of age or older. Subjects must be able and willing to give written informed consent [i.e., each subject will be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the study, and have a clear understanding of the study as well as the procedures involved, prior to signing the consent form].
• Subjects must exhibit a willingness to comply with the protocol and investigator's instructions.
• Subjects must have been previously diagnosed with unilateral or bilateral ocular hypertension at least six months prior to the screening visit.
• Subjects must exhibit baseline IOPs between 21 and 35 mmHg (inclusive); the average IOP between eyes must be ≤ 5 mmHg
• Subjects will be age matched to ocular hypotensive subjects
• Subjects must exhibit baseline IOPs between 12 and 20 mmHg (inclusive); the average IOP between eyes must be ≤ 5 mmHg

Exclusion Criteria

• Age less than nineteen years old.
• Women who are pregnant, lactating or of childbearing potential who are not using highly effective birth control measures.
• Aphakia or pseudophakia
• Best corrected visual acuity worse than 20/60 in either eye.
• Chronic or recurrent severe ocular inflammatory disease.
• Ocular infection or inflammation within three (3) months of screening visit.
• History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.
• Any abnormality preventing reliable tonometry of either eye.
• Previous exposure to: beta-adrenergic antagonists, topical prostaglandin analogues (including latanoprost, unoprostone, travoprost and bimatoprost) within six (6) weeks of the baseline visit; α-adrenergic agonists within two (2) weeks of the baseline visit; and cholinergic agonists and carbonic anhydrase inhibitors within five (5) days of the treatment initiation visit
• History of any severe ocular pathology (including severe dry eye) that would preclude the administration of a topical beta blocker, carbonic anhydrase inhibitor, or a topical prostaglandin.
• Any eye with a cup-to-disc ratio greater than 0.8.
• History of intraocular surgery.
• History of ocular laser surgery.
• History of severe or serious hypersensitivity to topical or systemic beta blockers, prostaglandins, or sulfa drugs.
• History of severe, unstable or uncontrolled cardiovascular, hepatic or renal disease.
• History of bronchial asthma or chronic obstructive pulmonary disease (COPD).
• Less than one month (prior to baseline) stable dosing regimen of any non-glaucoma medication that would affect IOP.
• Gonioscopy angle < 2.
• Inability to be dosed with treatment medication.
• Inability to discontinue contact lens wear.
• Therapy with any investigational agent within 30 days of screening.
• Use of any additional topical or systemic adjunctive ocular hypotensive medications during the study.
• History of open angle glaucoma (either primary open angle glaucoma or other cause of open angle glaucoma) or narrow angle glaucoma.